Calcitonin receptor localisation reveals potential sites of amylinergic signalling in rat nociceptive pathways
- Journal
- Brain structure & function (Q1)
- Published
- 10 November 2026
- Study design
- Unclassified
- Evidence level
- Level 5, Expert Opinion (CEBM 5)
- Authors
- Catarina Soares Potes, Nasrin Haghighi, António Avelino, Peter John Wookey, Fani Lourença Neto
- PMID
- 43004021
- DOI
- 10.1007/s00429-026-03221-6
Why clinicians should know about it
- Picked for Histology (paper of the day, 13 November 2026): Neuronal receptor localization with ultrastructural tissue analysis
Abstract
Amylin, a member of the calcitonin gene-related peptide (CGRP) family, modulates nociception through spinal mechanisms, but the anatomical organisation of its receptor system remains poorly characterised. Functional amylin receptors comprise the calcitonin receptor (CT receptor) associated with receptor activity-modifying proteins (RAMPs). We characterised the distribution of the CT receptor in the rat spinal cord and dorsal root ganglia (DRG) to identify potential sites of endogenous amylin signalling. CT receptor immunoreactivity was detected throughout the spinal cord, particularly in the dorsal horn and lateral spinal nucleus (LSp), and was associated predominantly with neuronal profiles. Ultrastructural analysis localised receptor immunoreactivity to unmyelinated axons in the superficial dorsal horn laminae. In DRG, CT receptor immunoreactivity was observed mainly in small sensory neurons, including peptidergic and non-peptidergic nociceptors. The limited co-localisation between amylin and CT receptor suggested that ligand and receptor are largely distributed in distinct neuronal populations, compatible with intercellular signalling. Amylin was also detected in myelinated sensory neurons, suggesting potential involvement in mechanosensory processing. These findings provide an anatomical framework for the distribution of the amylin receptor system across peripheral and spinal sensory pathways and identify potential substrates for amylinergic modulation.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.